Naltrexone Implant Sustained Release via Microsphere Coating
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current naltrexone implant preparation methods face issues such as microsphere rupture during tableting, uneven drug distribution, and slow drug release, leading to ineffective treatment of opioid addiction due to high relapse rates.
Innovation Solution
A method involving mixing naltrexone crystals with microspheres during tableting and using a specific coating process with a suspended drying method to form a skeleton structure and ensure uniform coating, preventing adhesion and burst release, while controlling the molecular weight of polylactic acid for optimal release rates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If naltrexone microspheres are tableted using conventional methods, then the implant can be formed, but the microspheres rupture during tableting causing uneven drug distribution and burst release
Solution Approach 1:
The microspheres are pre-coated with a protective coating layer before tableting. This preliminary coating action protects the microspheres from rupture during the subsequent tableting process, ensuring they maintain structural integrity while being compressed into the implant form.
Solution Approach 2:
The tableting process parameters are optimized by controlling the compression force and duration within specific ranges. This parameter control prevents excessive pressure that would cause microsphere rupture, while still achieving adequate tablet formation. The coating thickness and composition are also adjusted to provide optimal protection.
2Manufacturing precision
If the coating is applied using conventional methods, then the implant surface is coated, but the coating breaks due to adhesion between tablets
Solution Approach 1:
A release agent or lubricant is introduced as an intermediary substance between the coating and the tablet surface. This intermediary layer prevents direct adhesion between tablets during storage and handling, thereby preventing coating breakage without requiring complex coating equipment or processes.
Solution Approach 2:
The coating is designed as a flexible thin film with appropriate elasticity and adhesion properties. This thin film coating can accommodate minor movements and pressure variations without breaking, while maintaining a protective barrier. The coating formulation includes polymers that provide both adhesion to the substrate and flexibility to prevent fracture.
3Ease of operation
If naltrexone is administered orally, then the drug can be taken conveniently, but first-pass effects reduce bioavailability to only 5%-40%
Solution Approach 1:
The drug delivery system extracts the naltrexone from the gastrointestinal tract environment and first-pass metabolism pathway. By using an implantable formulation, the drug is delivered directly into the systemic circulation through subcutaneous or intramuscular implantation, bypassing the liver's first-pass effect and achieving near 100% bioavailability.
Solution Approach 2:
The conventional oral administration route (mechanical swallowing and gastrointestinal transit) is replaced with a direct implantation method. The implant serves as a reservoir that releases the drug through diffusion or erosion, substituting the complex gastrointestinal absorption process with a controlled release mechanism that bypasses metabolic degradation.
4Duration of action of moving object
If the elimination half-life is short (4 hours for naltrexone, 13 hours for metabolite), then the drug is quickly cleared, but patients must take medicine regularly or treatment becomes ineffective
Solution Approach 1:
The total drug dose is segmented into multiple smaller units contained within the implant matrix. The implant is designed to release these drug segments gradually over an extended period (months), transforming the need for frequent daily administration into a single implantation procedure that provides sustained therapeutic levels without requiring patient compliance for regular dosing.
Solution Approach 2:
The implant provides continuous drug release over an extended period, maintaining therapeutic drug levels in the bloodstream without interruption. This continuous action replaces the discontinuous pattern of daily oral dosing, eliminating gaps in therapy that occur when patients miss doses and ensuring uninterrupted opioid blockade.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach prevents microsphere rupture, ensures uniform drug distribution, and achieves a sustained release of naltrexone, significantly improving the pharmacodynamics and therapeutic effect by maintaining drug levels in the blood for an extended period.
Implementation Method 1
dissolving naltrexone and polylactic acid in an organic solvent to form microspheres
Implementation Method 2
dissolving naltrexone and polylactic acid in an organic solvent to form microspheres, and drying
Implementation Method 3
dissolving polylactic acid in an organic solvent to obtain the coating solution
Implementation Method 4
placing the solution in a coating pool, and then immersing the naltrexone implant tablets in the coating solution, and drying in the suspended state
Data Source
AI summary
The present invention relates to a technical field of pharmaceutical preparation, in particular to a preparation method of naltrexone implants, including the following steps: (1) dissolving naltrexone and polylactic acid in an organic solvent to form naltrexone microspheres, and drying; (2) placing the naltrexone microspheres in a heated tableting mold for tableting, and obtaining naltrexone implant tablets; (3) dissolving the polylactic acid in the organic solvent to obtain a coating solution, and placing the coating solution in a coating pool, and then immersing the naltrexone implant tablets in the coating solution, and drying in a suspended state.